Loading data
HPENYSE
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 34.3 bn USD | 30.13 bn USD | 29.14 bn USD | 28.5 bn USD |
| Research and development expense | 2.52 bn USD | 2.25 bn USD | 2.35 bn USD | 2.05 bn USD |
| Selling, general and administrative expense | 5.7 bn USD | 4.87 bn USD | 5.16 bn USD | 4.94 bn USD |
| Operating profit | -437 m USD | 2.19 bn USD | 2.09 bn USD | 782 m USD |
| Interest expense | 1.1 bn USD | 777 m USD | 709 m USD | 471 m USD |
| Profit before tax | -285 m USD | 2.95 bn USD | 2.23 bn USD | 876 m USD |
| Income tax expense | -342 m USD | 374 m USD | 205 m USD | 8 m USD |
| Net income (reported basis) | 57 m USD | 2.58 bn USD | 2.03 bn USD | 868 m USD |
| Net income attributable to common shareholders | -59 m USD | 2.55 bn USD | 2.03 bn USD | 868 m USD |
| Basic earnings per share | -0.04 USD/share | 1.95 USD/share | 1.56 USD/share | 0.67 USD/share |
| Diluted earnings per share | -0.04 USD/share | 1.93 USD/share | 1.54 USD/share | 0.66 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.